http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2675826-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fdfa839743282b4f2dd3575ed567676 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2017-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4092094420e7ec94abdfc7ecb8109a02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eede4064090c13d2199791bb2f217d19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a69bdfbc88c0fa2655402f91e6ef1e1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62c72b99eb7c3a9bb2503ac77eff6e1b |
| publicationDate | 2018-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2675826-C1 |
| titleOfInvention | Method for predicting the risk of development of hepatorenal syndrome in patients with portal hypertension of cirrhotic origin |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, in particular to a method for predicting the risk of developing hepatorenal syndrome in patients with portal hypertension of cirrhotic origin. Method essence is as follows: initially, investigate in patient the parameters of plasma creatinine, creatinine clearance, glomerular filtration rate, plasma potassium and sodium values. After that, the patient is injected intravenously with bolus of selective constrictor terlipressin at a dose of 1,000 mcg three times with an interval of 4–6 hours against the background of a short-term daily diuretic withdrawal, and after 6 hours thereafter, the above values are measured again. Compare the obtained results with the initial values of these indicators before the introduction of terlipressin. Percentage change in indicators is assessed in points. Summarize all definite points and, with a score of 3 or less, the risk of developing hepatorenal syndrome is considered as low, with a score of 4 to 8 – medium, with a score of 9 to 13 – high, with a score of 14 or more – very high. n EFFECT: invention provides an easy-to-use quantitative assessment of the risk of the development of hepatorenal syndrome in patients with portal hypertension of cirrhotic origin. n 1 cl, 3 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2792321-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2723748-C1 |
| priorityDate | 2017-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 125.